Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
07:20am, Monday, 12'th May 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointest
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Tuesday, 29'th Apr 2025
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
07:30am, Tuesday, 29'th Apr 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its f
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
03:30pm, Monday, 28'th Apr 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
01:05pm, Friday, 25'th Apr 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phas
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
12:05pm, Wednesday, 23'rd Apr 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
04:40pm, Tuesday, 25'th Mar 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Mee
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
10:55am, Tuesday, 25'th Mar 2025
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
07:30am, Wednesday, 19'th Mar 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorec
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
10:39am, Tuesday, 11'th Mar 2025
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chie
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
09:40am, Tuesday, 11'th Mar 2025
Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operat
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
04:48pm, Wednesday, 26'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
02:30pm, Tuesday, 25'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopha
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
08:33am, Monday, 24'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles
